Krystal Biotech, Inc. ($KRYS) CEO 2025 Pay Revealed
Krystal Biotech, Inc.'s CEO, Krish S. Krishnan, is estimated to have received $10,442,485 in compensation in 2025, marking a 49.42% decrease from 2024. The article also details significant insider selling activity, hedge fund movements in KRYS stock, and recent "Buy" ratings from Wall Street analysts with a median price target of $320.5.
KRYS PE Ratio & Valuation, Is KRYS Overvalued
Krystal Biotech Inc (KRYS) is currently considered undervalued, with a forward PS ratio of 11.03 compared to its five-year average of -10.78. Its fair price is estimated to be between $693.89 and $749.20, significantly higher than its current price of $260.95, indicating it is undervalued by 62.39%. The article also details KRYS's P/B ratio, FCF yield, and compares its P/S ratio to competitors.
[DEF 14A] Krystal Biotech, Inc. Definitive Proxy Statement
Krystal Biotech, Inc. (KRYS) has filed its definitive proxy statement (DEF 14A) for its 2026 annual meeting of stockholders to be held virtually on May 15, 2026. The proxy statement outlines proposals including the election of two Class III directors, the ratification of KPMG LLP as the independent auditor, a non-binding advisory vote on executive compensation, and the approval of the Non-Employee Director Compensation Policy. The company emphasizes its strong performance in 2025, particularly with its VYJUVEK product launch and pipeline advancement, while detailing its executive and director compensation practices designed to align with shareholder interests.
SG Americas Securities LLC Purchases 15,591 Shares of Krystal Biotech, Inc. $KRYS
SG Americas Securities LLC significantly increased its stake in Krystal Biotech (NASDAQ:KRYS) by 469.9% in the fourth quarter, acquiring an additional 15,591 shares to hold a total of 18,909 shares valued at $4.66 million. Krystal Biotech exhibits high institutional ownership at 86.29%, with several other major institutional investors also adjusting their positions. Analysts maintain a "Moderate Buy" rating for KRYS, with an average target price of $326.25 and some firms raising their price targets.
3 Insider-Owned Growth Companies With Up To 81% Earnings Expansion
This article highlights three growth companies with high insider ownership: Krystal Biotech (KRYS), Klaviyo (KVYO), and Sea Limited (SE). These companies are identified for their significant earnings growth forecasts, with Klaviyo expecting an 81.7% annual earnings expansion. The piece emphasizes the alignment of management interests with shareholder value in companies with substantial insider ownership.
KRYS News & Events
This article provides recent news and events related to Krystal Biotech (KRYS), including executive appointments, insider stock sales, increased institutional stakes, and several reports on the company's strong Q4 2025 earnings growth. It highlights the company's financial performance driven by VYJUVEK and its expanding clinical pipeline.
Q3 2024 Krystal Biotech Inc Earnings Call Transcript
Krystal Biotech Inc. reported strong Q3 2024 results, with VYJUVEK revenue exceeding $83.8 million and a 92% gross margin. The company is advancing its European market entry, securing early reimbursed access in France, and has positive early clinical data for KB301. Despite positive financial performance, the company faces challenges including litigation expenses, seasonal impacts on reimbursement, and potential revenue fluctuations due to patient treatment cycles and European pricing uncertainty.
Q4 2024 Krystal Biotech Inc Earnings Call Transcript
Krystal Biotech Inc. reported a strong Q4 and full year 2024, driven by the successful US launch of VYJUVEK and significant revenue growth. The company achieved positive EPS for six consecutive quarters and expanded its pipeline, while also acknowledging challenges such as treatment initiation delays and anticipated increases in operating expenses for 2025.
Vanguard disaggregates holdings after realignment; KRYS shows 0% ownership (KRYS)
The Vanguard Group has filed an amended Schedule 13G/A for Krystal Biotech Inc. (KRYS), reporting 0 shares and 0% beneficial ownership following an internal realignment effective January 12, 2026. This realignment disaggregates certain Vanguard subsidiaries for SEC reporting, meaning these subsidiaries will now report their holdings separately. The filing clarifies reporting structure rather than indicating active trading by Vanguard in KRYS.
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript
This article provides a transcript of Krystal Biotech Inc.'s participation in the TD Cowen Healthcare Conference on March 3, 2026. The discussion features Krish Krishnan, CEO, and Summa Krishnan, President of R&D, addressing the company's performance, particularly the return to growth for its product Vayjavec in Q4. They discuss the factors contributing to this growth, such as recent US Salesforce expansion and a label update allowing at-home self-dosing.
Wolfe Research Initiates Coverage on Krystal Biotech (NASDAQ:KRYS)
Wolfe Research has initiated coverage on Krystal Biotech (NASDAQ:KRYS) with a "peer perform" rating, aligning with the consensus "Moderate Buy" from analysts and an average price target of $326.25. The gene-therapy company recently surpassed quarterly earnings and revenue estimates, reporting a strong net margin. However, insider selling has occurred totaling over $34.5 million in recent months.
Krystal Biotech (KRYS) Valuation Check After Recent Pullback And Mixed Earnings Multiple Signals
Krystal Biotech (KRYS) has seen a recent stock pullback with mixed signals on its valuation. Vestra's fair value estimate of $314.00 suggests the stock is undervalued, driven by expectations of high margins and global expansion. However, a comparatively high forward P/E ratio compared to peers and the broader US biotech sector presents a differing, more cautious signal about its current market price.
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Moderate Buy" from Brokerages
Krystal Biotech, Inc. (NASDAQ:KRYS) has received a "Moderate Buy" consensus rating from analysts, with an average one-year price target of $326.25. The company recently surpassed earnings and revenue expectations, and despite some insider stock sales, a significant portion of the company is still owned by insiders and institutional investors. Several brokerage firms have recently raised their price targets for KRYS.
Krystal Biotech Inc (KRYS) Stock News & Articles
This article provides an overview of Krystal Biotech Inc (KRYS), a biotechnology firm specializing in genetic medicines for rare diseases, highlighting its flagship product VYJUVEK and its diverse pipeline. It includes current stock data for KRYS and references a recent article discussing how the Phase 3 data for MRNA, SRPT, and KRYS will influence the 2026 performance of the SPDR S&P Biotech ETF (XBI).
Total operating expenses of Krystal Biotech Inc Unsponsored BDR – BMFBOVESPA:K1YS34
This article displays the total operating expenses for Krystal Biotech Inc Unsponsored BDR, traded as K1YS34 on BMFBOVESPA. It presents financial data for different periods, including value, change, and percentage change. The content is primarily a data presentation page from TradingView.
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $325
BofA Securities has reiterated its Buy rating on Krystal Biotech (KRYS.US). The firm also increased its target price for the biotech company to $325. This indicates a positive outlook on Krystal Biotech's future performance by BofA Securities.
KRYS SEC Filings - Krystal Biotech 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Krystal Biotech (KRYS) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. It highlights the company's focus on genetic medicines like VYJUVEK and its pipeline programs, offering AI-powered summaries of recent filings detailing financial results, clinical updates, and regulatory developments. The page serves as a central hub for investors and traders to access Krystal Biotech's official regulatory disclosures and stay informed on company progress.
Krystal Biotech Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance
Krystal Biotech, a small-cap pharmaceuticals and biotechnology company, reported robust financial results for Q4 2025, with strong operating cash flow, net profit growth of 55.54%, and high cash reserves. Despite a low inventory turnover ratio, the company has shown strong market performance, outperforming the S&P 500 year-to-date and surging 50.36% over the past year.
KRYS SEC Filings - Krystal Biotech 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Krystal Biotech (KRYS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. Stock Titan offers AI-powered summaries of these documents to help investors quickly understand financial results, clinical updates, and regulatory developments. Recent filings cover financial results, regulatory approvals, clinical milestones, and insider transactions.
(KRYS) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Krystal Biotech Inc. (NASDAQ: KRYS), identifying positive near-term sentiment within a long-term strong context, despite a mid-term weak bias. It highlights that resistance is being tested and details specific institutional trading strategies, including long, breakout, and short setups with precise entry, target, and stop-loss levels. The report also offers multi-timeframe signal analysis and access to AI-generated real-time signals for sophisticated risk management.
A Look At Krystal Biotech (KRYS) Valuation After Updated Vyjuvek Label And Pipeline Momentum
Krystal Biotech (KRYS) is receiving attention due to an updated FDA label for its gene therapy, Vyjuvek, and anticipation for its KB803 candidate. The company shows a 36.79% one-year return and trades at a potential 21% discount to analyst targets. While some views suggest it's undervalued with a fair value of $371.25, others point to its rich P/E ratio compared to industry averages, indicating potentially high investor expectations.
Why has Krystal Biotech (KRYS) dropped 11.5% following its most recent earnings announcement?
Krystal Biotech's shares dropped 11.5% following its recent earnings announcement, despite exceeding EPS estimates for Q4 2025. The decline is attributed to revenue falling short of expectations and recent downward revisions in analyst estimates. The company provided a 2026 financial outlook, updated on its pipeline, and currently holds a Zacks Rank #3 (Hold).
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krystal Biotech (KRYS) shares have decreased by 11.5% since its last earnings report, underperforming the S&P 500. Despite beating EPS estimates with $1.70, the company missed revenue expectations, reporting $107.1 million, which was solely from Vyjuvek sales. Krystal Biotech is advancing a robust clinical pipeline, with several genetic medicine candidates in development across various medical fields, though estimates for the stock have trended downward during the past month.
Why has Krystal Biotech (KRYS) dropped 11.5% following its most recent earnings announcement?
Krystal Biotech (KRYS) shares dropped 11.5% due to its Q4 2025 revenue missing estimates, despite strong EPS. The company reported $107.1 million in revenue against an expected $109 million, though Vyjuvek sales grew and EPS beat expectations. Outlook includes ongoing pricing discussions for Vyjuvek in Europe and progress on various clinical-stage genetic therapies.
Vyjuvek Label Update And KB803 Progress Reshape Krystal Biotech Story
Krystal Biotech (NasdaqGS:KRYS) has seen an updated FDA label for its gene therapy Vyjuvek, which treats epidermolysis bullosa, and its candidate KB803 has progressed in development. These advancements aim to expand the treated patient pool and diversify Krystal Biotech's product offerings, transforming it from a single-product company into a broader franchise in epidermolysis bullosa care. Investors should monitor real-world adoption of Vyjuvek, KB803's trial progress, and reimbursement discussions to assess the company's long-term financial stability and market position.
Vyjuvek Label Update And KB803 Progress Reshape Krystal Biotech Story
Krystal Biotech (NasdaqGS:KRYS) has seen significant developments with the FDA approval of an updated label for Vyjuvek, addressing epidermolysis bullosa, and the advancement of KB803 within its pipeline. These events are crucial for investors as they expand the potential patient pool for Vyjuvek and introduce a second potential product, thereby reshaping the company's product reach, risk profile, and future revenue mix within the rare disease market. The company is transitioning from a single-product focus to a broader franchise in epidermolysis bullosa, with implications for its addressable market and long-term financial stability.
Braidwell LP Cuts Holdings in Krystal Biotech, Inc. $KRYS
Braidwell LP reduced its stake in Krystal Biotech by 28.5% in the third quarter, selling 207,410 shares but still maintaining it as its 10th-largest holding. Despite this, other institutions like Avoro Capital Advisors and State Street Corp increased their positions. Krystal Biotech reported strong Q4 earnings, beating estimates, and holds a "Moderate Buy" consensus rating from Wall Street analysts.
Avoro Capital Advisors LLC Purchases 117,777 Shares of Krystal Biotech, Inc. $KRYS
Avoro Capital Advisors LLC increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.4% in the third quarter, purchasing an additional 117,777 shares to reach a total of 2,777,777 shares, now valued at approximately $490.4 million. This makes Krystal Biotech Avoro's fifth-largest holding, representing 6.3% of its portfolio. Analysts have a "Moderate Buy" rating for KRYS with an average price target of $326.25, following the company's Q3 earnings beat with an EPS of $1.70 and revenue of $107.11 million.
Krystal Biotech Stock Surges on Q4 Beat, But Valuation Questions Linger After CEO Share Sale
Krystal Biotech exceeded fourth-quarter expectations with $107.1 million in Vyjuvek revenue and a strong balance sheet, leading to a 42.95% one-year stock rally. However, recent insider share sales by the CEO and concerns about valuation, along with the company's reliance on Vyjuvek, are tempering investor enthusiasm. The article highlights both the company's impressive operational performance and the lingering questions regarding its long-term valuation and pipeline execution.
Assessing Krystal Biotech (KRYS) Valuation After Q4 2025 Beat And CEO Stock Sale
Krystal Biotech (KRYS) exceeded analyst expectations in Q4 2025 with strong earnings and record revenue driven by their gene therapy, Vyjuvek. Despite a short-term stock dip, the company shows significant long-term growth, and valuation models suggest it might be undervalued. The company plans aggressive international expansion for 2026.
First Trust Advisors LP Has $43.85 Million Stake in Krystal Biotech, Inc. $KRYS
First Trust Advisors LP significantly increased its stake in Krystal Biotech, Inc. (KRYS) by 11.7% in the third quarter, holding 248,392 shares valued at $43.85 million. The stock currently holds a consensus "Moderate Buy" rating from analysts with an average price target of $326.25, following multiple upgrades and price target increases. Despite institutional buying, corporate insiders have been net sellers, offloading approximately $34.54 million worth of shares in the past 90 days.
8,212 Shares in Krystal Biotech, Inc. $KRYS Bought by WINTON GROUP Ltd
WINTON GROUP Ltd purchased a new position of 8,212 shares in Krystal Biotech, Inc. (NASDAQ:KRYS) during the third quarter, valued at approximately $1.45 million. This comes as Krystal Biotech exceeded quarterly earnings and revenue estimates, leading to several analyst upgrades and a consensus "Moderate Buy" rating with a target price of $326.25. However, the company has seen significant insider selling recently, with insiders offloading 129,164 shares worth about $34.54 million over the past 90 days.
The Bull Case For Krystal Biotech (KRYS) Could Change Following Q4 Beat And CEO Stock Sales
Krystal Biotech (KRYS) exceeded Q4 2025 earnings and revenue expectations, while its CEO sold $6.58 million in stock. This article explores how these developments, coupled with the RMAT designation for KB707, might influence the company's investment narrative, which is largely driven by its VYJUVEK therapy. It also touches on varying analyst forecasts and the company's projected financial performance.
The Bull Case For Krystal Biotech (KRYS) Could Change Following Q4 Beat And CEO Stock Sales
Krystal Biotech (KRYS) recently reported stronger-than-expected Q4 2025 financial results, while its President and CEO executed significant pre-planned stock sales. The article examines how this combination of financial outperformance and insider selling impacts the investment narrative, which is heavily reliant on the commercial success of its VYJUVEK therapy. It also touches upon the FDA's RMAT designation for KB707, providing a modest long-term diversification argument.
[Form 4] Krystal Biotech, Inc. Insider Trading Activity
Krystal Biotech, Inc.'s President and CEO, Krishnan Krish, sold 25,000 shares of common stock on March 4, 2026, through multiple open-market transactions. These sales were executed under a pre-arranged Rule 10b5-1 trading plan established in September 2025. After these transactions, Krish retains significant direct and indirect holdings in the company.
Krystal Biotech (KRYS) R&D president sells 25,000 shares under 10b5-1 plan
Suma Krishnan, President of R&D and a director at Krystal Biotech (KRYS), sold 25,000 shares of the company's common stock on March 4, 2026. The sales were conducted through open-market transactions, priced between $256.68 and $266.93 per share, as part of a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Krishnan directly holds 1,403,155 shares and indirectly owns an additional 140,000 shares through trusts.
Krystal Biotech (NASDAQ:KRYS) Insider Sells $6,580,250.00 in Stock
Suma Krishnan, an insider at Krystal Biotech (NASDAQ:KRYS), sold 25,000 shares of the company's stock for $6,580,250 on March 4th, reducing her ownership by 1.75%. This transaction comes after Krystal Biotech reported strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $326.25. The stock experienced a slight dip of 2.6% to $253.69 following the sale.
[144] Krystal Biotech, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Krystal Biotech, Inc. (KRYS). The filing indicates a proposed sale of 25,000 shares of common stock with an aggregate market value of $6,595,000, acquired on March 31, 2017, as founders' shares. The sale is set to occur on March 4, 2026, via Morgan Stanley Smith Barney LLC on NASDAQ.
Segall Bryant & Hamill LLC Lowers Stock Position in Krystal Biotech, Inc. $KRYS
Segall Bryant & Hamill LLC significantly reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 42.6% in the third quarter, impacting its total holdings to 85,263 shares valued at $15.05 million. Despite insider selling, the company's stock has performed well, beating quarterly earnings estimates with $1.70 EPS and $107.11M in revenue, leading to positive analyst revisions and a "Moderate Buy" consensus rating with a target price of $326.25. Krystal Biotech specializes in gene therapies for rare dermatological diseases, with its lead product candidate KB103 targeting dystrophic epidermolysis bullosa.
Daniel Janney Sells 11,803 Shares of Krystal Biotech (NASDAQ:KRYS) Stock
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney sold 11,803 shares of the company's stock on February 27th at an average price of $275.59, totaling over $3.25 million. This recent sale, along with other transactions earlier that week, reduced his stake by 13.87% to 73,293 shares. The company recently reported better-than-expected earnings and revenue, and analysts have a "Moderate Buy" rating with an average price target of $326.25.
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million
Daniel Janney, a Director at Krystal Biotech, Inc. (NASDAQ:KRYS), sold 11,803 shares of common stock for a total of $3.25 million on February 27, 2026. This sale was executed under a Rule 10b5-1 trading plan, following a significant 54% surge in Krystal Biotech shares over the past year. Despite the insider sale, the company recently reported strong financial results for Q4 2025, exceeding analyst expectations for both EPS and revenue.
Alta Bioequities linked to Krystal Biotech (KRYS) director sells 11,803 shares
Alta Bioequities, L.P., an entity connected to Krystal Biotech director Daniel Janney, sold 11,803 shares of KRYS common stock on February 27, 2026. The sales, executed at weighted average prices around $275-$276 per share, were conducted under a pre-established Rule 10b5-1 trading plan adopted in November 2025. Following these transactions, Alta Bioequities, L.P. retained 73,293 shares of the company.
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million
Daniel Janney, a director at Krystal Biotech, Inc. (NASDAQ:KRYS), sold 11,803 shares of common stock totaling $3.25 million on February 27, 2026, under a Rule 10b5-1 trading plan. This sale occurred after the company's shares surged significantly over the past year, and Krystal Biotech recently reported strong Q4 2025 financial results, surpassing analyst expectations for EPS and revenue. Following the transactions, Janney directly beneficially owns 73,293 shares through Alta Bioequities, L.P.
Krystal Biotech (NASDAQ: KRYS) CEO reports new equity awards and tax share surrenders
Krystal Biotech's CEO, Krish S. Krishnan, reported the vesting of restricted and performance stock units, which converted into common shares. He also received new equity awards, including stock options for 45,249 shares and 18,140 restricted stock units, both vesting over four years. Notably, shares were surrendered to the company for tax withholding purposes rather than being sold on the open market.
Krystal Biotech (KRYS) R&D chief logs new awards, PSU vesting and tax trades
Krystal Biotech's President of R&D, Suma Krishnan, reported various equity compensation events and tax-related share disposals. These included the vesting of 22,500 performance stock units and 4,000 restricted stock units, along with new grants of 18,100 stock options, 7,256 time-based RSUs, and 43,536 performance stock units. The report also detailed indirect ownership through her spouse and family trusts, including their own vesting and tax-withholding transactions.
TD Asset Management Boosts Stake in Krystal Biotech
TD Asset Management Inc. has significantly increased its stake in Krystal Biotech, a clinical-stage biotechnology company specializing in gene therapies for rare dermatological diseases. The firm's investment grew by 124.5% in the third quarter, bringing its total ownership to 45,080 shares valued at $7.958 million. This increased institutional confidence signals optimism regarding Krystal Biotech's future pipeline and market prospects.
Krystal Biotech, Inc. $KRYS Position Increased by William Blair Investment Management LLC
William Blair Investment Management LLC significantly increased its stake in Krystal Biotech (KRYS) by 63.9% in Q3, now holding 149,302 shares valued at $26.36 million. Institutional investors collectively own about 86.29% of the company, with various other funds also materially boosting their positions. Despite recent insider selling, analysts maintain a "Moderate Buy" consensus rating with a target price of $326.25, following multiple price target increases.
TD Asset Management Inc Boosts Position in Krystal Biotech, Inc. $KRYS
TD Asset Management Inc. significantly increased its stake in Krystal Biotech, Inc. (KRYS) by 124.5% in the third quarter, now holding 45,080 shares valued at approximately $7.96 million. This boost comes amidst positive analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $326.25, reflecting recent target increases by firms like Jefferies and Citigroup. However, the article also notes substantial insider selling, with 116,611 shares sold collectively for about $30 million over the last 90 days, even as KRYS shares experienced a recent 6.1% drop.
KRYS Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Krystal Biotech (KRYS), including its income statement, balance sheet, cash flow, and key financial ratios for fiscal year 2025. The company demonstrates strong financial health with high profitability, significant revenue growth, low leverage, and robust liquidity, scoring 95/100 on its Financial Profile. Despite a neutral Piotroski F-Score, KRYS shows a low bankruptcy risk with a high Altman Z-Score.
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Krystal Biotech, Inc. (NASDAQ:KRYS) has received a "Moderate Buy" consensus rating from ten analysts, with an average 12-month price target of $326.25. Several firms, including Jefferies, Chardan, BofA, TD Cowen, and HC Wainwright, recently raised their price targets for the company. Despite positive analyst sentiment, company insiders have been net sellers, disposing of over $30 million worth of shares in the past 90 days.
